Author Correction: Cancer-associated Histone H3 N-terminal arginine mutations disrupt PRC2 activity and impair differentiation
Benjamin A. Nacev(University of Pittsburgh), C. David Allis(Rockefeller University), Sagarika Tiwari(University of Pittsburgh), William D. Tap(Memorial Sloan Kettering Cancer Center), Tom W. Muir(Princeton University), Benjamin A. Garcia(Washington University in St. Louis), Nicholas D. Socci, Douglas Barrows(Rockefeller University), Christian Pacheco(Rockefeller University), Matthew R. Paul(Rockefeller University), Alexey A. Soshnev(The University of Texas at San Antonio), Sébastien Monette(Memorial Sloan Kettering Cancer Center), Michelle M. Mitchener(Princeton University), Yekaterina Perez(University of Pennsylvania), Yakshi Dabas(Rockefeller University), Michael Gruß(University of Pittsburgh), Samantha C. St. Jean(Memorial Sloan Kettering Cancer Center), Fang Yan(Memorial Sloan Kettering Cancer Center), Thomas Carroll(Rockefeller University)
Cited by 0
Related Papers
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET
|Nature Medicine|2012|3.7k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k
Histone and chromatin cross-talk
|Current Opinion in Cell Biology|2003|1.2k
How many human proteoforms are there?
|Nature Chemical Biology|2018|945